RANI Rani Therapeutics (RANI) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001856725
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
26
13F, latest reported quarter
What the filings say about RANI
Insiders, 180 days
+$50.0K net bought
2 buyers
Rani Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Rani Therapeutics Holdings, Inc. insiders bought a net $50.0K of stock across 95 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Oct 23, 2025.
- The trade is 1.7% of the 2,119,334 shares held after it.
- 1 other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director IMRAN MIR A bought about $24.8K of RANI on Jul 21, 2026; 1 other insider bought within 30 days and 26 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (6 buys, 1 sale), the last on Dec 27, 2024.
- +48.8% median (+46.8% mean) 90-day return after 5 previous buys.
- The trade is 7.5% of the 469,736 shares held after it.
- 1 other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Imran Talat bought about $25.2K of RANI on Jul 17, 2026; 1 other insider bought within 30 days and 26 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 4.0% of the 9,689 shares held after it.
- No other insider sold within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technical Officer Javadi Alireza sold about $301 of RANI on Mar 27, 2026; 26 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 17, 2022.
- The trade is 100.0% of the 2,083,334 shares held after it.
- No other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director IMRAN MIR A bought about $1.3M of RANI on Oct 23, 2025, the largest insider purchase at the company since 2023; 26 funds added in the latest 13F quarter.Context
- 29 earlier Form 4 trades (code P or S) here by this insider (26 buys, 3 sales), the last on Oct 20, 2025.
- -21.4% median (-17.7% mean) 90-day return after 26 previous buys.
- The trade is 168.1% of the 2,379,194 shares held after it.
- No other insider sold within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider South Cone Investments Limited Partnership sold about $11.1M of RANI on Oct 21, 2025, the largest insider sale at the company on our record; 26 funds added in the latest 13F quarter.95 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$50.0K over 180 days
+$24.8K of it by a 10%+ holder
more than 73% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
26 funds bought in last quarter
below 64% of Pharma & Biotech
Revenue
+58.9% year over year
more than 79% of Pharma & Biotech
Margin
-1817.1% net margin
below 91% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
8.8% of the float short (float per yahoo 2026-10-26) · 11.6 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch RANI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-74.9%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns RANI: institutional holders (13F)
13F holdings, latest reported quarter
10,369,159 sh
$7.9M
8,500,000 sh
$6.5M
7,500,000 sh
$5.7M
4,562,985 sh
$3.5M
2,329,459 sh
$1.8M
Congress trades in RANI
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
RANI planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
RANI mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$87.1K position · as of 2026-06-30
0.1%
Invesco Nasdaq Biotechnology ETF
$4.9K position · as of 2026-05-31
0.0%
ProShares Ultra Nasdaq Biotechnology
$3.4K position · as of 2026-05-31
0.0%
Fidelity Extended Market Index Fund
$382.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$634.9K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$58.9K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $50.0K bought by insiders over 180 days, 26 funds added last quarter. Each figure is a federal filing, dated the day it went public.
RANI financials
Revenue growth
+58.9%
XBRL, annual
Net margin
-1817.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM RANI
| FY Dec 2025 | $1.6M |
| FY Dec 2024 | $1.0M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | $2.7M |
| Jun 2026 | $1.7M |
| Mar 2026 | $1.7M |
| Dec 2025 | $1.5M |
| Sep 2025 | $0 |
| Jun 2025 | $0 |
| Mar 2025 | $172.0K |
| Dec 2024 | $1.0M |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
-618.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM RANI
| FY Dec 2025 | -1,817% |
| FY Dec 2024 | -2,920% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -432.7% |
| Mar 2026 | -411.8% |
| Dec 2025 | -705.3% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -870.3% |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$20.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM RANI
| FY Dec 2025 | -$18.8M |
| FY Dec 2024 | -$35.8M |
| FY Dec 2023 | -$52.5M |
| FY Dec 2022 | -$48.1M |
| FY Dec 2021 | -$32.8M |
| Jun 2026 | -$9.1M |
| Mar 2026 | -$6.5M |
| Dec 2025 | $294.0K |
| Sep 2025 | -$5.1M |
| Jun 2025 | -$5.8M |
| Mar 2025 | -$8.2M |
| Dec 2024 | -$8.7M |
| Sep 2024 | -$8.5M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term 2025-12-31 (6 months older than the period end) plus current 2025-12-31 (6 months older than the period end); equity 2026-06-30
Debt to equity RANI
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 12.36x |
| FY Dec 2023 | 2.28x |
| FY Dec 2022 | 0.79x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 12.36x |
| Sep 2024 | 9.07x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt RANI
| FY Dec 2025 | n/a |
| FY Dec 2024 | -1.44x |
| FY Dec 2023 | -1.74x |
| FY Dec 2022 | -1.60x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -2.04x |
| Jun 2025 | -1.80x |
| Mar 2025 | -1.64x |
| Dec 2024 | -1.44x |
| Sep 2024 | -1.39x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-179.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity RANI
| FY Dec 2025 | -169.6% |
| FY Dec 2024 | -404.1% |
| FY Dec 2023 | -136.6% |
| FY Dec 2022 | -72.6% |
| FY Dec 2021 | n/a |
| Jun 2026 | -179.1% |
| Mar 2026 | -232.3% |
| Dec 2025 | -169.6% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | -1,373% |
| Dec 2024 | -404.1% |
| Sep 2024 | -272.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-77.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets RANI
| FY Dec 2025 | -62.3% |
| FY Dec 2024 | -63.5% |
| FY Dec 2023 | -40.9% |
| FY Dec 2022 | -26.3% |
| FY Dec 2021 | n/a |
| Jun 2026 | -77.5% |
| Mar 2026 | -77.5% |
| Dec 2025 | -62.3% |
| Sep 2025 | -105.5% |
| Jun 2025 | -97.9% |
| Mar 2025 | -76.8% |
| Dec 2024 | -63.5% |
| Sep 2024 | -49.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital RANI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-141.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed RANI
| FY Dec 2025 | -122.2% |
| FY Dec 2024 | -159.9% |
| FY Dec 2023 | -86.3% |
| FY Dec 2022 | -56.5% |
| FY Dec 2021 | -52.7% |
| Jun 2026 | -141.8% |
| Mar 2026 | -164.9% |
| Dec 2025 | -122.2% |
| Sep 2025 | -624.6% |
| Jun 2025 | -420.8% |
| Mar 2025 | -232.5% |
| Dec 2024 | -159.9% |
| Sep 2024 | -119.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing RANI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value RANI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield RANI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing RANI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.6M | $1.0M | $0 | $0 |
| Operating income | -$38.3M | -$53.3M | -$66.1M | -$63.5M |
| Net income | -$29.7M | -$30.0M | -$34.0M | -$30.6M |
| EPS (diluted) | -0.45 | -1.05 | -1.33 | -1.28 |
| Operating cash flow | -$18.7M | -$35.5M | -$51.2M | -$46.5M |
| Cash | $18.6M | $3.8M | $5.9M | $27.0M |
| Long-term debt | $0 | $9.6M | $24.5M | $29.1M |
SEC XBRL, fiscal years, as known on 2026-10-27
RANI Stock Sonar score 6/7 axes
Find similar shapesCompareRANI ranks highest on financial health (99th percentile) and growth (79th), and lowest on profitability (22nd), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
RANI filings, in plain words
Are Rani Therapeutics insiders buying or selling RANI?
In the 180 days to 2026-10-27, Rani Therapeutics insiders were net buyers, a net $50.0K across purchases and sales reported on Form 4, by 2 buyers.
Read the full summary
In the 180 days to 2026-10-27, Rani Therapeutics insiders were net buyers of RANI, a net $50.0K across purchases and sales reported on Form 4 by 2 buyers. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
